Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib

BACKGROUND: Sunitinib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors, and stem cell factor receptor (KIT). The ability of soluble (s)KIT, VEGF-A, sVEGFR-2, and sVEGFR-3 to predict clinical outcome was analyzed in 61 patients with previously t...

Descripción completa

Detalles Bibliográficos
Autores principales: Keyvanjah, Kiana, DePrimo, Samuel E, Harmon, Charles S, Huang, Xin, Kern, Kenneth A, Carley, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499375/
https://www.ncbi.nlm.nih.gov/pubmed/22897944
http://dx.doi.org/10.1186/1479-5876-10-165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499375/
https://www.ncbi.nlm.nih.gov/pubmed/22897944
http://dx.doi.org/10.1186/1479-5876-10-165

Ejemplares similares